Homology Medicines, Inc. (FIXX) Analysts See $-0.34 EPS

July 14, 2018 - By Sheila Anderson

Analysts expect Homology Medicines, Inc. (NASDAQ:FIXX) to report $-0.34 EPS on August, 13.After having $-4.21 EPS previously, Homology Medicines, Inc.’s analysts see -91.92 % EPS growth. The stock increased 0.09% or $0.02 during the last trading session, reaching $21.76. About 58,547 shares traded. Homology Medicines, Inc. (NASDAQ:FIXX) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company has market cap of $809.22 million. The Company’s proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. It currently has negative earnings. The company's various set of AAVHSCs allows firm to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities?gene editing and gene therapy.

Homology Medicines, Inc. (NASDAQ:FIXX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.